Literature DB >> 2449238

Comparison of mammary serum antigen (MSA) and CA15-3 levels in the serum of patients with breast cancer.

N P Sacks1, S A Stacker, C H Thompson, J P Collins, I S Russell, J A Sullivan, I F McKenzie.   

Abstract

Serum levels of mammary serum antigen (MSA) and CA15-3 were evaluated in 135 individuals in order to determine their single and combined value in the diagnosis and monitoring of breast cancer. Raised MSA levels (greater than 300 IU) were found in 68% of patients with Stage I and II breast cancer compared to only 3% having raised CA15-3 levels (greater than 40 U ml-1). Of 38 patients with Stage IV breast cancer, 95% had raised levels of MSA and CA15-3 combined with each test individually detecting 82% of those with Stage IV disease. No correlation was found between MSA and CA15-3 levels. Four patients being treated for breast cancer were followed over a 5-17 week period; MSA levels correlated with disease course in 3 and CA-15 in 2. The overall sensitivity, specificity and accuracy in detecting breast cancer were 76%, 91% and 96% for MSA; and 47%, 95% and 97% for CA15-3 respectively. When both tests were used together combined evaluation gave the highest sensitivity (84%) and specificity (100%). MSA seems to be superior to CA15-3 for early breast cancer diagnosis and a combination of the two tests gave the best results for metastatic disease.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2449238      PMCID: PMC2002392          DOI: 10.1038/bjc.1987.297

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  11 in total

Review 1.  Monoclonal antibodies reactive with breast tumor-associated antigens.

Authors:  J Schlom; D Colcher; P H Hand; J Greiner; D Wunderlich; M Weeks; P B Fisher; P Noguchi; S Pestka; D Kufe
Journal:  Adv Cancer Res       Date:  1985       Impact factor: 6.242

2.  Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer.

Authors:  D F Hayes; V R Zurawski; D W Kufe
Journal:  J Clin Oncol       Date:  1986-10       Impact factor: 44.544

3.  Reporting results of cancer treatment.

Authors:  A B Miller; B Hoogstraten; M Staquet; A Winkler
Journal:  Cancer       Date:  1981-01-01       Impact factor: 6.860

4.  [CA 15-3 is present as a novel tumor marker in the sera of patients with breast cancer and other malignancies].

Authors:  Y Gang; I Adachi; H Ohkura; H Yamamoto; Y Mizuguchi; K Abe
Journal:  Gan To Kagaku Ryoho       Date:  1985-12

5.  A new breast carcinoma antigen defined by a monoclonal antibody.

Authors:  S A Stacker; C Thompson; C Riglar; I F McKenzie
Journal:  J Natl Cancer Inst       Date:  1985-11       Impact factor: 13.506

Review 6.  Carcinoembryonic antigen in breast cancer. Clinical review.

Authors:  D B Beard; C M Haskell
Journal:  Am J Med       Date:  1986-02       Impact factor: 4.965

7.  Usefulness of serial serum carcinoembryonic antigen (CEA) determinations during anticancer therapy or long-term follow-up of gastrointestinal carcinoma.

Authors:  M Ravry; C G Moertel; A J Schutt; V L Go
Journal:  Cancer       Date:  1974-10       Impact factor: 6.860

8.  Serial plasma carcinoembryonic antigen measurements during treatment of metastatic breast cancer.

Authors:  A W Mughal; G N Hortobagyi; H A Fritsche; A U Buzdar; H Y Yap; G R Blumenschein
Journal:  JAMA       Date:  1983-04-08       Impact factor: 56.272

9.  [Evaluation of a tumor-associated antigen CA 15-3 in the sera of patients with breast cancer].

Authors:  T Ogawa; M Izuo; H Morita; T Ishida; Y Iino; K Hoshino; T Yokoe; H Suzuki; S Murata; S Matsuzaki
Journal:  Gan No Rinsho       Date:  1986-01

10.  Monoclonal antibodies against human milk-fat globule membranes detecting differentiation antigens of the mammary gland and its tumors.

Authors:  J Hilkens; F Buijs; J Hilgers; P Hageman; J Calafat; A Sonnenberg; M van der Valk
Journal:  Int J Cancer       Date:  1984-08-15       Impact factor: 7.396

View more
  10 in total

1.  CEA and CA 15-3 in primary and recurrent breast cancer.

Authors:  P J O'Dwyer; M J Duffy; F O'Sullivan; E McDermott; P Losty; N J O'Higgins
Journal:  World J Surg       Date:  1990 Sep-Oct       Impact factor: 3.352

2.  Circulating CA 15-3 levels in the postsurgical follow-up of breast cancer patients and in non-malignant diseases.

Authors:  R Colomer; A Ruibal; J Genollá; D Rubio; J M Del Campo; R Bodi; L Salvador
Journal:  Breast Cancer Res Treat       Date:  1989-03       Impact factor: 4.872

3.  Mammary serum antigen (MSA) in advanced breast cancer.

Authors:  Y C Smart; J F Stewart; L D Bartlett; J H Brien; J F Forbes; R C Burton
Journal:  Breast Cancer Res Treat       Date:  1990-07       Impact factor: 4.872

4.  CA15-3, CASA, MSA, and TPS as diagnostic serum markers in breast cancer.

Authors:  P L Devine; M A Duroux; R J Quin; M A McGuckin; G J Joy; B G Ward; C W Pollard
Journal:  Breast Cancer Res Treat       Date:  1995-06       Impact factor: 4.872

5.  Immunosuppressive acidic protein serum levels in breast cancer patients in a reference to CA 15-3 levels.

Authors:  A D Cohen; Y Shoenfeld; J Gopas; Y Cohen
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

6.  Simple method for comparing reliability of two serum tumour markers in breast carcinoma.

Authors:  D P O'Brien; D B Gough; R Skehill; H Grimes; H F Given
Journal:  J Clin Pathol       Date:  1994-02       Impact factor: 3.411

7.  Mucin-like cancer-associated antigen (MCA) compared with CA 15-3 in advanced breast cancer.

Authors:  G G Steger; R Mader; K Derfler; K Moser; C Dittrich
Journal:  Klin Wochenschr       Date:  1989-08-17

8.  The association of mammary serum antigen (MSA) with the histopathological findings in localised breast cancer.

Authors:  J J Tjandra; I Busmanis; I S Russell; J P Collins; R G Reed; I F McKenzie
Journal:  Br J Cancer       Date:  1988-12       Impact factor: 7.640

9.  An evaluation of mucin-like carcinoma associated antigen (MCA) in breast cancer.

Authors:  E H Cooper; M A Forbes; A K Hancock; J J Price; D Parker
Journal:  Br J Cancer       Date:  1989-05       Impact factor: 7.640

10.  Epithelial mucin core antigen (EMCA) in assessing therapeutic response in advanced breast cancer--a comparison with CA15.3.

Authors:  A R Dixon; M R Price; C W Hand; P E Sibley; C Selby; R W Blamey
Journal:  Br J Cancer       Date:  1993-11       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.